The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global PD-1 and PD-L1 Inhibitor Market Research Report 2025

Global PD-1 and PD-L1 Inhibitor Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1732259

No of Pages : 97

Ask Your Query
Synopsis
Highlights
The global PD-1 and PD-L1 Inhibitor market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of PD-1 and PD-L1 Inhibitor include Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Bristol Myers Squibb and Hengrui Medicine, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for PD-1 and PD-L1 Inhibitor in Lung Cancer is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Monoclonal Antibody, which accounted for % of the global market of PD-1 and PD-L1 Inhibitor in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Inhibitor.
The PD-1 and PD-L1 Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global PD-1 and PD-L1 Inhibitor market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1 and PD-L1 Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Merck
Bristol-Myers Squibb
Pfizer
Sanofi
Regeneron Pharmaceuticals
Roche
AstraZeneca
Bristol Myers Squibb
Hengrui Medicine
Beigene
Innovent Biologics
Junshi Biosciences
Akeso
Alphamab Oncology
Product Type Insights
Global markets are presented by PD-1 and PD-L1 Inhibitor type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the PD-1 and PD-L1 Inhibitor are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
PD-1 and PD-L1 Inhibitor segment by Type
Monoclonal Antibody
Bispecific Antibody
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the PD-1 and PD-L1 Inhibitor market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the PD-1 and PD-L1 Inhibitor market.
PD-1 and PD-L1 Inhibitor segment by Application
Lung Cancer
Stomach Cancer
Breast Cancer
Rectal Cancer
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the PD-1 and PD-L1 Inhibitor market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the PD-1 and PD-L1 Inhibitor industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1 and PD-L1 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index
1 PD-1 and PD-L1 Inhibitor Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Inhibitor
1.2 PD-1 and PD-L1 Inhibitor Segment by Type
1.2.1 Global PD-1 and PD-L1 Inhibitor Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Monoclonal Antibody
1.2.3 Bispecific Antibody
1.3 PD-1 and PD-L1 Inhibitor Segment by Application
1.3.1 Global PD-1 and PD-L1 Inhibitor Sales Comparison by Application: (2022-2028)
1.3.2 Lung Cancer
1.3.3 Stomach Cancer
1.3.4 Breast Cancer
1.3.5 Rectal Cancer
1.3.6 Others
1.4 Global PD-1 and PD-L1 Inhibitor Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PD-L1 Inhibitor Revenue 2017-2028
1.4.2 Global PD-1 and PD-L1 Inhibitor Sales 2017-2028
1.4.3 PD-1 and PD-L1 Inhibitor Market Size by Region: 2017 Versus 2021 Versus 2028
2 PD-1 and PD-L1 Inhibitor Market Competition by Manufacturers
2.1 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2017-2022)
2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2017-2022)
2.3 Global PD-1 and PD-L1 Inhibitor Average Price by Manufacturers (2017-2022)
2.4 Manufacturers PD-1 and PD-L1 Inhibitor Manufacturing Sites, Area Served, Product Type
2.5 PD-1 and PD-L1 Inhibitor Market Competitive Situation and Trends
2.5.1 PD-1 and PD-L1 Inhibitor Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest PD-1 and PD-L1 Inhibitor Players Market Share by Revenue
2.5.3 Global PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 and PD-L1 Inhibitor Retrospective Market Scenario by Region
3.1 Global PD-1 and PD-L1 Inhibitor Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global PD-1 and PD-L1 Inhibitor Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.3.1 North America PD-1 and PD-L1 Inhibitor Sales by Country
3.3.2 North America PD-1 and PD-L1 Inhibitor Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.4.1 Europe PD-1 and PD-L1 Inhibitor Sales by Country
3.4.2 Europe PD-1 and PD-L1 Inhibitor Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific PD-1 and PD-L1 Inhibitor Market Facts & Figures by Region
3.5.1 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region
3.5.2 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.6.1 Latin America PD-1 and PD-L1 Inhibitor Sales by Country
3.6.2 Latin America PD-1 and PD-L1 Inhibitor Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.7.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country
3.7.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global PD-1 and PD-L1 Inhibitor Historic Market Analysis by Type
4.1 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2017-2022)
4.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2017-2022)
4.3 Global PD-1 and PD-L1 Inhibitor Price by Type (2017-2022)
5 Global PD-1 and PD-L1 Inhibitor Historic Market Analysis by Application
5.1 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2017-2022)
5.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2017-2022)
5.3 Global PD-1 and PD-L1 Inhibitor Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Corporation Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Bristol Myers Squibb
6.8.1 Bristol Myers Squibb Corporation Information
6.8.2 Bristol Myers Squibb Description and Business Overview
6.8.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
6.8.5 Bristol Myers Squibb Recent Developments/Updates
6.9 Hengrui Medicine
6.9.1 Hengrui Medicine Corporation Information
6.9.2 Hengrui Medicine Description and Business Overview
6.9.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
6.9.5 Hengrui Medicine Recent Developments/Updates
6.10 Beigene
6.10.1 Beigene Corporation Information
6.10.2 Beigene Description and Business Overview
6.10.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
6.10.5 Beigene Recent Developments/Updates
6.11 Innovent Biologics
6.11.1 Innovent Biologics Corporation Information
6.11.2 Innovent Biologics PD-1 and PD-L1 Inhibitor Description and Business Overview
6.11.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
6.11.5 Innovent Biologics Recent Developments/Updates
6.12 Junshi Biosciences
6.12.1 Junshi Biosciences Corporation Information
6.12.2 Junshi Biosciences PD-1 and PD-L1 Inhibitor Description and Business Overview
6.12.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
6.12.5 Junshi Biosciences Recent Developments/Updates
6.13 Akeso
6.13.1 Akeso Corporation Information
6.13.2 Akeso PD-1 and PD-L1 Inhibitor Description and Business Overview
6.13.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
6.13.5 Akeso Recent Developments/Updates
6.14 Alphamab Oncology
6.14.1 Alphamab Oncology Corporation Information
6.14.2 Alphamab Oncology PD-1 and PD-L1 Inhibitor Description and Business Overview
6.14.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
6.14.5 Alphamab Oncology Recent Developments/Updates
7 PD-1 and PD-L1 Inhibitor Manufacturing Cost Analysis
7.1 PD-1 and PD-L1 Inhibitor Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitor
7.4 PD-1 and PD-L1 Inhibitor Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 PD-1 and PD-L1 Inhibitor Distributors List
8.3 PD-1 and PD-L1 Inhibitor Customers
9 PD-1 and PD-L1 Inhibitor Market Dynamics
9.1 PD-1 and PD-L1 Inhibitor Industry Trends
9.2 PD-1 and PD-L1 Inhibitor Market Drivers
9.3 PD-1 and PD-L1 Inhibitor Market Challenges
9.4 PD-1 and PD-L1 Inhibitor Market Restraints
10 Global Market Forecast
10.1 PD-1 and PD-L1 Inhibitor Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitor by Type (2023-2028)
10.1.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitor by Type (2023-2028)
10.2 PD-1 and PD-L1 Inhibitor Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitor by Application (2023-2028)
10.2.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitor by Application (2023-2028)
10.3 PD-1 and PD-L1 Inhibitor Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitor by Region (2023-2028)
10.3.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitor by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global PD-1 and PD-L1 Inhibitor Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global PD-1 and PD-L1 Inhibitor Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global PD-1 and PD-L1 Inhibitor Market Competitive Situation by Manufacturers in 2021
Table 5. Global PD-1 and PD-L1 Inhibitor Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2017-2022)
Table 7. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market PD-1 and PD-L1 Inhibitor Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers PD-1 and PD-L1 Inhibitor Manufacturing Sites and Area Served
Table 11. Manufacturers PD-1 and PD-L1 Inhibitor Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global PD-1 and PD-L1 Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 and PD-L1 Inhibitor as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global PD-1 and PD-L1 Inhibitor Sales by Region (2017-2022) & (K Units)
Table 16. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2017-2022)
Table 17. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2017-2022)
Table 19. North America PD-1 and PD-L1 Inhibitor Sales by Country (2017-2022) & (K Units)
Table 20. North America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2017-2022)
Table 21. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2017-2022)
Table 23. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2017-2022) & (K Units)
Table 24. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2017-2022)
Table 25. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2017-2022)
Table 31. Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2017-2022) & (K Units)
Table 32. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2017-2022)
Table 33. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2017-2022)
Table 39. Global PD-1 and PD-L1 Inhibitor Sales by Type (2017-2022) & (K Units)
Table 40. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2017-2022)
Table 41. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global PD-1 and PD-L1 Inhibitor Revenue Share by Type (2017-2022)
Table 43. Global PD-1 and PD-L1 Inhibitor Price by Type (2017-2022) & (US$/Unit)
Table 44. Global PD-1 and PD-L1 Inhibitor Sales (K Units) by Application (2017-2022)
Table 45. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2017-2022)
Table 46. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global PD-1 and PD-L1 Inhibitor Revenue Share by Application (2017-2022)
Table 48. Global PD-1 and PD-L1 Inhibitor Price by Application (2017-2022) & (US$/Unit)
Table 49. Merck Corporation Information
Table 50. Merck Description and Business Overview
Table 51. Merck PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Merck PD-1 and PD-L1 Inhibitor Product
Table 53. Merck Recent Developments/Updates
Table 54. Bristol-Myers Squibb Corporation Information
Table 55. Bristol-Myers Squibb Description and Business Overview
Table 56. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product
Table 58. Bristol-Myers Squibb Recent Developments/Updates
Table 59. Pfizer Corporation Information
Table 60. Pfizer Description and Business Overview
Table 61. Pfizer PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Pfizer PD-1 and PD-L1 Inhibitor Product
Table 63. Pfizer Recent Developments/Updates
Table 64. Sanofi Corporation Information
Table 65. Sanofi Description and Business Overview
Table 66. Sanofi PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Sanofi PD-1 and PD-L1 Inhibitor Product
Table 68. Sanofi Recent Developments/Updates
Table 69. Regeneron Pharmaceuticals Corporation Information
Table 70. Regeneron Pharmaceuticals Description and Business Overview
Table 71. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product
Table 73. Regeneron Pharmaceuticals Recent Developments/Updates
Table 74. Roche Corporation Information
Table 75. Roche Description and Business Overview
Table 76. Roche PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Roche PD-1 and PD-L1 Inhibitor Product
Table 78. Roche Recent Developments/Updates
Table 79. AstraZeneca Corporation Information
Table 80. AstraZeneca Description and Business Overview
Table 81. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. AstraZeneca PD-1 and PD-L1 Inhibitor Product
Table 83. AstraZeneca Recent Developments/Updates
Table 84. Bristol Myers Squibb Corporation Information
Table 85. Bristol Myers Squibb Description and Business Overview
Table 86. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product
Table 88. Bristol Myers Squibb Recent Developments/Updates
Table 89. Hengrui Medicine Corporation Information
Table 90. Hengrui Medicine Description and Business Overview
Table 91. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product
Table 93. Hengrui Medicine Recent Developments/Updates
Table 94. Beigene Corporation Information
Table 95. Beigene Description and Business Overview
Table 96. Beigene PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Beigene PD-1 and PD-L1 Inhibitor Product
Table 98. Beigene Recent Developments/Updates
Table 99. Innovent Biologics Corporation Information
Table 100. Innovent Biologics Description and Business Overview
Table 101. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Innovent Biologics PD-1 and PD-L1 Inhibitor Product
Table 103. Innovent Biologics Recent Developments/Updates
Table 104. Junshi Biosciences Corporation Information
Table 105. Junshi Biosciences Description and Business Overview
Table 106. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product
Table 108. Junshi Biosciences Recent Developments/Updates
Table 109. Akeso Corporation Information
Table 110. Akeso Description and Business Overview
Table 111. Akeso PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Akeso PD-1 and PD-L1 Inhibitor Product
Table 113. Akeso Recent Developments/Updates
Table 114. Alphamab Oncology Corporation Information
Table 115. Alphamab Oncology Description and Business Overview
Table 116. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product
Table 118. Alphamab Oncology Recent Developments/Updates
Table 119. Production Base and Market Concentration Rate of Raw Material
Table 120. Key Suppliers of Raw Materials
Table 121. PD-1 and PD-L1 Inhibitor Distributors List
Table 122. PD-1 and PD-L1 Inhibitor Customers List
Table 123. PD-1 and PD-L1 Inhibitor Market Trends
Table 124. PD-1 and PD-L1 Inhibitor Market Drivers
Table 125. PD-1 and PD-L1 Inhibitor Market Challenges
Table 126. PD-1 and PD-L1 Inhibitor Market Restraints
Table 127. Global PD-1 and PD-L1 Inhibitor Sales Forecast by Type (2023-2028) & (K Units)
Table 128. Global PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Type (2023-2028)
Table 129. Global PD-1 and PD-L1 Inhibitor Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 130. Global PD-1 and PD-L1 Inhibitor Revenue Market Share Forecast by Type (2023-2028)
Table 131. Global PD-1 and PD-L1 Inhibitor Sales Forecast by Application (2023-2028) & (K Units)
Table 132. Global PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Application (2023-2028)
Table 133. Global PD-1 and PD-L1 Inhibitor Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 134. Global PD-1 and PD-L1 Inhibitor Revenue Market Share Forecast by Application (2023-2028)
Table 135. Global PD-1 and PD-L1 Inhibitor Sales Forecast by Region (2023-2028) & (K Units)
Table 136. Global PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Region (2023-2028)
Table 137. Global PD-1 and PD-L1 Inhibitor Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 138. Global PD-1 and PD-L1 Inhibitor Revenue Market Share Forecast by Region (2023-2028)
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PD-1 and PD-L1 Inhibitor
Figure 2. Global PD-1 and PD-L1 Inhibitor Market Share by Type in 2021 & 2028
Figure 3. Monoclonal Antibody Product Picture
Figure 4. Bispecific Antibody Product Picture
Figure 5. Global PD-1 and PD-L1 Inhibitor Market Share by Application in 2021 & 2028
Figure 6. Lung Cancer
Figure 7. Stomach Cancer
Figure 8. Breast Cancer
Figure 9. Rectal Cancer
Figure 10. Others
Figure 11. Global PD-1 and PD-L1 Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global PD-1 and PD-L1 Inhibitor Market Size (2017-2028) & (US$ Million)
Figure 13. Global PD-1 and PD-L1 Inhibitor Sales (2017-2028) & (K Units)
Figure 14. PD-1 and PD-L1 Inhibitor Sales Share by Manufacturers in 2021
Figure 15. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers in 2021
Figure 16. The Global 5 and 10 Largest PD-1 and PD-L1 Inhibitor Players: Market Share by Revenue in 2021
Figure 17. PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 18. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2017-2022)
Figure 19. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region in 2021
Figure 20. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2017-2022)
Figure 21. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region in 2021
Figure 22. United States PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Canada PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Germany PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. France PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. U.K. PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Italy PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Russia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. China PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Japan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. South Korea PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. India PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Australia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. China Taiwan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Indonesia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Thailand PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Malaysia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Mexico PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Brazil PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Argentina PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. UAE PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of PD-1 and PD-L1 Inhibitor by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of PD-1 and PD-L1 Inhibitor
Figure 46. Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitor
Figure 47. PD-1 and PD-L1 Inhibitor Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock